This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Cancer-Associated Thrombosis
  • /
  • Role of direct oral anticoagulants in the treatmen...
Guideline

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism

Read time: 1 mins
Last updated:1st Sep 2018
Status: Live
Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH


Venous thromboembolism (VTE) is an unfortunately prevalent complication in patients with active cancer 1. Direct oral anticoagulants (DOACs) have been approved for the treatment of VTE in general populations. However, for cancer patients, most guidelines continue to recommend low molecular weight heparin (LMWH) monotherapy for at least 3–6 months, owing to the lack of cancer‐specific data regarding the use of these agents 2-4. Both recent emerging data from clinical practice experience and new randomized clinical trials (RCTs) specifically for cancer patients may alter this approach. This statement incorporates these new data, and provides guidance on the current role of DOACs in the treatment of cancer‐associated thrombosis.

Read full guidelines